|Awarded On||September 14, 2022|
|Title||Advanced Protein Therapeutics core|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Jennifer Maynard|
|Cancer Sites||Brain and Other Nervous System, Breast, Pancreas|
Protein therapeutics are the fastest growing pharmaceutical sector and have helped many millions of patients. These therapeutics include antibodies that bind tumor cells to recruit immune responses and enzymes which starve tumors of essential nutrients. Compared with chemotherapies and radiation, proteins are generally safer and less toxic. However, the activities required to discover, engineer, and produce protein therapeutics require specialized skills and resources, which presents barriers that limit the ability of most cancer researchers to translate their research into new therapeutics. Recognizing that over 80 percent of FDA-approved therapies are originally derived from academic resea...